http://www.nejm.org/doi/full/10.1056/NEJMoa1804710
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger. (Funded by the National Cancer Institute and others; TAILORx ClinicalTrials.gov number, NCT00310180 .)
2006년부터 시작된 연구 결과가 이제 발표되었다고... 물론 그 사이 항암치료를 필수적으로 처방한 것은 의료계 관행이었다고 해야 할지...
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger. (Funded by the National Cancer Institute and others; TAILORx ClinicalTrials.gov number, NCT00310180 .)
2006년부터 시작된 연구 결과가 이제 발표되었다고... 물론 그 사이 항암치료를 필수적으로 처방한 것은 의료계 관행이었다고 해야 할지...